This work provides a resource for understanding the impact of CD133+ CSCs (CSCs) on the progression of HCC in terms of tumor-immune interactions and has potential therapeutic and prognostic implications for identifying ways to advance immunotherapy research. The gene discussed is PROM1; the disease is neoplasm.